AstraZeneca's ENHERTU Shows Stronger Progression-Free Survival in HER2-Mutant Lung Cancer Trial
Event summary
- AstraZeneca and Daiichi Sankyo's ENHERTU demonstrated a median progression-free survival of 14.3 months as a first-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in the DESTINY-Lung04 Phase III trial.
- The trial showed a 37.0% reduction in the risk of disease progression or death compared to the standard of care (pembrolizumab plus chemotherapy).
- Objective response rate with ENHERTU was 70.0% versus 44.5% with the standard of care.
- Results were presented at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea.
The big picture
The DESTINY-Lung04 trial results position ENHERTU as a potential new standard of care for HER2-mutant non-small cell lung cancer, a disease with limited treatment options. This success underscores the growing importance of targeted therapies in oncology and reinforces AstraZeneca's leadership in developing innovative cancer treatments. The results also highlight the strategic collaboration between AstraZeneca and Daiichi Sankyo in advancing antibody-drug conjugate technology.
What we're watching
- Regulatory Pathway
- Whether the positive results will accelerate regulatory approval for ENHERTU as a first-line treatment for HER2-mutant NSCLC.
- Market Competition
- How AstraZeneca and Daiichi Sankyo will position ENHERTU against existing and emerging therapies in the HER2-mutant NSCLC space.
- Commercial Strategy
- The pace at which AstraZeneca and Daiichi Sankyo can expand access to ENHERTU in global markets, particularly in regions with high incidence of HER2-mutant lung cancer.
Related topics